Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01835002
Other study ID # TESOLA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2012
Est. completion date August 2015

Study information

Verified date March 2021
Source Okuvision GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to expand the safety assessment of repeated applications of an electrical current from a DTL-like electrode in patients with RP.


Description:

This is a single-arm open label interventional safety trial with RP patients, who receive weekly TES for 6 months on 1 eye followed by observation for another 6 months without stimulation. The primary outcome measure is safety, indicated by the frequency and severity of adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date August 2015
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - patients with retinitis pigmentosa (rod-cone dystrophy) after prescription of electrical stimulation by an ophthalmologist - adult patients who are capable of giving consent, - Visual acuity = 0.02 - because the electrode is to be positioned on the eye at home, the patient or his family members should have sufficient fine motor skills (assessment by the study physician) - the patient must be capable of giving consent and a medical assessment that he/she is able to participate in the whole study according to the protocol Exclusion Criteria: - diabetic retinopathy - neovascularisation of any origin - after arterial or venous occlusion - after retinal detachment - silicone oil tamponade - dry or exudative age-related macular degeneration - macular edema - all forms of glaucoma - any form of corneal degeneration that reduces visual acuity - systemic diseases that are difficult to control or manage, that could endanger the normal study schedule - patients in a permanently poor general condition, which could hinder the regular attendance at control examinations in the clinic - forms of mental illness related to the bipolar affective and schizoid-affective disorders, and all forms of dementia - simultaneous participation in another interventional study or history of interventions whose effect may still persist

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcorneal electrostimulation
Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.

Locations

Country Name City State
Denmark Glostrup Hospital and Kennedy Center Glostrup
Germany University Eye Clinic Bonn Bonn
Germany Augenzentrum München Munich
Germany University Eye Clinic Regensburg Regensburg
Germany Zentrum für seltene Netzhauterkrankungen, AugenZentrum Siegburg Siegburg
Germany Centre for Ophthalmology at the eye clinic Tübingen Tübingen
Norway Oslo University Hospital Oslo

Sponsors (1)

Lead Sponsor Collaborator
Okuvision GmbH

Countries where clinical trial is conducted

Denmark,  Germany,  Norway, 

References & Publications (6)

Gekeler F; Arbeitsgruppe Elektrostimulation des Department für Augenheilkunde am Universitäts-Klinikum Tübingen. [Transcorneal electrostimulation]. Ophthalmologe. 2012 Feb;109(2):129-35. doi: 10.1007/s00347-011-2450-6. German. — View Citation

Jolly JK, Wagner SK, Martus P, MacLaren RE, Wilhelm B, Webster AR, Downes SM, Charbel Issa P, Kellner U, Jägle H, Rüther K, Bertelsen M, Bragadóttir R, Prener Holtan J, van den Born LI, Sodi A, Virgili G, Gosheva M, Pach J, Zündorf I, Zrenner E, Gekeler F — View Citation

Naycheva L, Schatz A, Röck T, Willmann G, Messias A, Bartz-Schmidt KU, Zrenner E, Gekeler F. Phosphene thresholds elicited by transcorneal electrical stimulation in healthy subjects and patients with retinal diseases. Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7440-8. doi: 10.1167/iovs.12-9612. — View Citation

Röck T, Schatz A, Naycheva L, Gosheva M, Pach J, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Willmann G, Gekeler F. [Effects of transcorneal electrical stimulation in patients with Stargardt's disease]. Ophthalmologe. 2013 Jan;110(1):68-73. doi: 10.1007/s00347-012-2749-y. German. — View Citation

Schatz A, Arango-Gonzalez B, Fischer D, Enderle H, Bolz S, Röck T, Naycheva L, Grimm C, Messias A, Zrenner E, Bartz-Schmidt KU, Willmann G, Gekeler F. Transcorneal electrical stimulation shows neuroprotective effects in retinas of light-exposed rats. Invest Ophthalmol Vis Sci. 2012 Aug 15;53(9):5552-61. doi: 10.1167/iovs.12-10037. — View Citation

Schatz A, Röck T, Naycheva L, Willmann G, Wilhelm B, Peters T, Bartz-Schmidt KU, Zrenner E, Messias A, Gekeler F. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Invest Ophthalmol Vis Sci. 2011 Jun 23;52(7):4485-96. doi: 10.1167/iovs.10-6932. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary ophthalmic examinations visual acuity slit lamp microscopy for examination of the anterior and posterior segment intraocular pressure measurement visual field examination Optical coherence tomography (OCT) Digital colour fundus photography 6 months
Secondary Questionnaires Questionnaires to collect the patient's perceived benefits of treatment and handling of the device 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2
Completed NCT04315025 - Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa Phase 1/Phase 2